BBK Worldwide is very excited to be participating in the 9th Annual SCOPE Summit for Clinical Ops Executives. Taking place February 12 – 15 in Orlando FL, SCOPE will offer three days of in-depth discussions addressing the operational, technological and data-related aspects of clinical trial planning and management, with 18 different conferences, 3 plenary keynote sessions and interactive breakout discussions.
For our latest eBook 21st Century Research Champions, we reached out to physicians to gain a deeper understanding about their attitudes and actions with regard to clinical research, and explored tested strategies in building relationships with physicians to enhance patient recuritment. As it turns out, physicians were more than happy to provide their insights into the value of referring physician programs and to elaborate on their willingness to contribute to clinical research. We interviwed Dr. Eliott Rosenstein -- a physician with more than 40 years of experience and Director of the Institute for Rheumatic and Autoimmune diseases -- to get his take on our latest eBook and the importance of referring physicians in clinical trial patient recruitment.
Picture this: a clammy Nicolas Cage sits hunched forward in the driver’s seat of a $5m hypercar, gripping the top of the steering wheel and staring at an undefined point just beyond the camera.
His grip on the wheel tightens and he punches the accelerator.
In a cacophony of protesting rubber and tire smoke, he’s Gone in 60 Seconds.
Sound familiar? I’m making a tenuous but spellbinding opening remark to get our blood flowing about advertising. Not just advertising in general but also, more specifically, patient recruitment advertising.
When patients find themselves interacting with information about their health and well-being, it is the responsibility of healthcare professionals to ensure that these interactions are as meaningful and productive as they can be. In this regard, the informed consent process is among the most important facets of clinical research currently undergoing a digital transformation, and pharmaceutical companies must continue to adopt eConsent across the board.
In an age where patients have more choice about treatment options (just think about how the treatment guidelines have evolved for multiple sclerosis or rheumatoid arthritis in the last 10 years for example,) and more clinical trials are being conducted by fewer investigators, there has been a constant upward pressure on competition for clinical trial patients, even as sponsors and third party recruitment companies becomes more innovative and proactive in their approaches to marketing their trials.
It’s clear that the clinical team for each study is tasked with creating and managing an individual study budget. The problem is one-off study purchases do not accrue the benefits of volume discounting. Of course, there are numerous and complicated financial arrangements sponsors make with service providers to create optimal rates for clinical trial support – but what about the simple construct of, “buy one shirt, get another for free?”
Facebook recently held a special, invite-only breakfast for drug marketers about recruitment for clinical trials, educating them on targeting consumers and announcing their latest initiative, “clinical trial strategy”.
Part 1 in this series of blogs on the role of referring physicians in clinical research chronicled the factors that have led to study sponsors’ lack of confidence in physician referrals as an effective patient recruitment strategy. In Part 2 of this series on Research Champions referring physicians spoke for themselves through primary research conducted by BBK Worldwide. Today, we look at best practices that lead to referring physician programs that generate compelling results.
Part 1 in this series of blogs on the role of referring physicians in clinical research chronicled the factors that have led to study sponsors’ lack of confidence in physician referrals as an effective patient recruitment strategy. This installment gives voice to the referring physicians themselves by sharing results of primary research conducted by BBK Worldwide.
Long ago, in a land far away, principal investigators were expected to “accrue study subjects” using their network of physician colleagues. Enrolling subjects from one’s patient panel was discouraged as therapeutic misconception might impugn study results. As a result, acceptable enrollment might run from 36 to 60 months or more.
Investigators would commonly send a “Dear Doctor” letter to others within their hospital or to their personal connections. Rarely did these letters produce effective results. Over time, referring physician programs altogether lost value and credibility due to a few commonly held beliefs: